As it ramps up its rollout of the first twice-yearly HIV pre-exposure prophylaxis (PrEP) medicine, Gilead Sciences is tapping into a beloved early-aughts track to familiarize consumers with Yeztugo.

Following an extensive Middle East military build-up by the U.S. in recent weeks, the U.S. and Israel on Feb. 28 launched attacks across Iran. In response, Iran launched retaliatory attacks on Israel, ...

Ahead of a rescheduled meeting of the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP), Department of Health and Human Services (HHS) Secretary | ...

Quotient Sciences, a CDMO that specializes in "niche and smaller volume" drugs that it says are often overlooked by bigger contract manufacturers, has ...

With some 12 years as CEO under his belt, Bavarian Nordic’s Paul Chaplin is telegraphing his exit from the Denmark-based ...

Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based ...

Since the start of the millennium, podcasts have gone from nonexistent to numbering in the millions, and Edison Research ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities.  | In a Worker Adjustment and Retraining Notification Act alert filed this ...

A handful of pharmas and celebrities are joining forces with the National Bleeding Disorders Foundation (NBDF) for a ...

While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ...

After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its up-and-coming immunology powerhouse. | Two years and five indications later ...